Last updated on April 2018

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Brief description of study

The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.

Clinical Study Identifier: TX203028

Contact Investigators or Research Sites near you

Start Over

Jan Wilson

University of South Florida-Morsani College of Medicine
Tampa, FL USA
  Connect »